- |||||||||| dodekin (F8-IL12) / Philogen
Trial completion date, Trial primary completion date: DODEKA: Safety and Early Signs of Efficacy of IL12-L19L19. (clinicaltrials.gov) - Apr 8, 2024
P1, N=94, Recruiting,
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| dodekin (F8-IL12) / Philogen
Trial completion date, Trial primary completion date: DODEKA: Safety and Early Signs of Efficacy of IL12-L19L19. (clinicaltrials.gov) - Dec 8, 2022
P1, N=94, Recruiting,
Initial signs of activity have been observed. Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| dodekin (F8-IL12) / Philogen
Trial completion date, Trial primary completion date: DODEKA: Safety and Early Signs of Efficacy of IL12-L19L19. (clinicaltrials.gov) - Apr 20, 2022
P1, N=94, Recruiting,
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| dodekin (F8-IL12) / Philogen
Clinical, Journal: Inference of molecular structure for characterization and improvement of clinical grade immunocytokines. (Pubmed Central) - Dec 16, 2021
Here, we performed structure investigations on clinical grade fusion proteins L19-IL2, IL12-L19L19 and L19L19-IL2 to elucidate their quaternary organization...Comparison with 3D reconstructions obtained from negative-stain electron microscopy revealed marked flexibility associated to the linker regions connecting the cytokine and the antibody components of the chimeric proteins. Collectively, our results indicate that low-resolution molecular structure characterizations provide useful complementary insights for the quality control of immunocytokines, constituting a powerful tool to guide the design and the subsequent optimization steps towards clinical enhancement of these chimeric protein reagents.
|
